Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Brief description of study

The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ cell tumor compared to the standard treatment. We want to know if the accelerated chemotherapy using the same drugs is beneficial but not more toxic than the standard chemotherapy regimen. The accelerated chemotherapy is experimental.


Clinical Study Identifier: s18-01969
ClinicalTrials.gov Identifier: NCT02582697
Principal Investigator: Mark E Weinblatt
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.